TW406130B - Methods of in vitro predicting a patient's susceptibility to increase periodontal disease severity and the kits therefor - Google Patents
Methods of in vitro predicting a patient's susceptibility to increase periodontal disease severity and the kits therefor Download PDFInfo
- Publication number
- TW406130B TW406130B TW085109393A TW85109393A TW406130B TW 406130 B TW406130 B TW 406130B TW 085109393 A TW085109393 A TW 085109393A TW 85109393 A TW85109393 A TW 85109393A TW 406130 B TW406130 B TW 406130B
- Authority
- TW
- Taiwan
- Prior art keywords
- patient
- periodontal disease
- dual gene
- disease
- sequence
- Prior art date
Links
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000000338 in vitro Methods 0.000 title claims 4
- 206010071602 Genetic polymorphism Diseases 0.000 claims abstract 13
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 230000009977 dual effect Effects 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- 201000010099 disease Diseases 0.000 claims description 57
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 39
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 38
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 33
- 102100039065 Interleukin-1 beta Human genes 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 13
- 239000013068 control sample Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 11
- 238000009941 weaving Methods 0.000 claims 3
- 230000006862 enzymatic digestion Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 15
- 230000002079 cooperative effect Effects 0.000 description 12
- 230000029087 digestion Effects 0.000 description 11
- 206010065687 Bone loss Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 235000015170 shellfish Nutrition 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000003239 periodontal effect Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 201000001245 periodontitis Diseases 0.000 description 6
- 201000009906 Meningitis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000007565 gingivitis Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000034391 chronic adult periodontitis Diseases 0.000 description 2
- 208000001277 chronic periodontitis Diseases 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000005562 gingival recession Diseases 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101100193519 Caenorhabditis elegans qui-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101001076386 Homo sapiens Interleukin-1 family member 10 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/510,696 US5686246A (en) | 1995-08-03 | 1995-08-03 | Detecting genetic predisposition to periodontal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW406130B true TW406130B (en) | 2000-09-21 |
Family
ID=24031795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW085109393A TW406130B (en) | 1995-08-03 | 1996-08-03 | Methods of in vitro predicting a patient's susceptibility to increase periodontal disease severity and the kits therefor |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5686246A (enExample) |
| EP (2) | EP0853630A4 (enExample) |
| JP (1) | JP4042811B2 (enExample) |
| KR (1) | KR19990036067A (enExample) |
| CN (1) | CN1198166A (enExample) |
| AR (1) | AR003182A1 (enExample) |
| AT (1) | ATE207927T1 (enExample) |
| AU (1) | AU719965B2 (enExample) |
| BR (1) | BR9604044A (enExample) |
| CA (1) | CA2228424C (enExample) |
| DE (1) | DE69616478T2 (enExample) |
| DK (1) | DK0769560T3 (enExample) |
| ES (1) | ES2166866T3 (enExample) |
| ID (1) | ID17246A (enExample) |
| IL (1) | IL123053A (enExample) |
| IS (1) | IS4653A (enExample) |
| MX (1) | MX9800941A (enExample) |
| MY (1) | MY132156A (enExample) |
| NO (1) | NO980439L (enExample) |
| NZ (1) | NZ315836A (enExample) |
| PT (1) | PT769560E (enExample) |
| SI (1) | SI9620098A (enExample) |
| TW (1) | TW406130B (enExample) |
| WO (1) | WO1997006180A1 (enExample) |
| ZA (1) | ZA966585B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951721B2 (en) * | 1996-02-12 | 2005-10-04 | Gene Logic Inc. | Method for determining the haplotype of a human BRCA1 gene |
| GB9621129D0 (en) | 1996-10-10 | 1996-11-27 | Duff Gordon W | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| US6210877B1 (en) * | 1997-03-10 | 2001-04-03 | Interleukin Genetics, Inc. | Prediction of coronary artery disease |
| US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
| US7820383B2 (en) | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
| US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
| AU9217198A (en) * | 1997-09-03 | 1999-03-22 | Oncormed | Method for predicting prognosis and treatment response for genetically based abnormalities |
| IL135957A0 (en) * | 1997-11-07 | 2001-05-20 | Interleukin Genetics Inc | Diagnostics and therapeutics for chronic obstructive airway disease |
| US6746839B1 (en) | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US6130042A (en) * | 1998-03-05 | 2000-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for diagnosing periodontal disease |
| US20050032077A1 (en) * | 1998-03-10 | 2005-02-10 | Duff Gordon W. | Detecting genetic predisposition to sight-threatening diabetic retinopathy |
| WO1999054707A2 (en) * | 1998-04-21 | 1999-10-28 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6733967B1 (en) | 1998-04-21 | 2004-05-11 | Interleukin Genetics, Inc. | Fetal testing for prediction of low birth weight |
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| US20090023147A1 (en) * | 1999-08-30 | 2009-01-22 | Kenneth Kornman | Diagnostics and therapeutics for osteoporosis |
| US6225069B1 (en) * | 2000-02-29 | 2001-05-01 | The Board Of Trustees Of The University Of Arkansas | Methods to identify genetic predisposition to alzheimer's disease |
| US20030124524A1 (en) * | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
| DE10112348A1 (de) * | 2001-03-13 | 2002-10-02 | Antje Roetger | Nukleotidträger zur Diagnose und Therapie oraler Erkrankungen |
| US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
| EP1463745A4 (en) * | 2001-11-19 | 2007-11-07 | Interleukin Genetics Inc | FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES |
| US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
| US20070264645A1 (en) * | 2002-01-25 | 2007-11-15 | Kenneth Kornman | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| US20030148288A1 (en) * | 2002-02-01 | 2003-08-07 | Yi-Wei Tang | Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof |
| US20040229228A1 (en) * | 2002-07-25 | 2004-11-18 | Northwestern University | Il-1 genotype in early kidney allograft rejection |
| BR0314552A (pt) * | 2002-09-30 | 2005-08-09 | Novartis Ag | Métodos para prognosticar elevações de colesterol durante terapia imunossupressora |
| EP1680513B1 (en) * | 2003-08-08 | 2010-12-01 | Interleukin Genetics, Inc. | Diagnostic for osteoporosis |
| US20070003947A1 (en) * | 2005-01-18 | 2007-01-04 | Decarlo Arthur A | Detecting genetic risk for periodontal disease |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US8105775B2 (en) * | 2005-10-25 | 2012-01-31 | Interleukin Genetics, Inc. | IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes |
| WO2008060627A2 (en) * | 2006-11-15 | 2008-05-22 | Interleukin Genetics, Inc. | The il-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same |
| US7925192B2 (en) * | 2007-09-04 | 2011-04-12 | Ricoh Company, Ltd. | Developing roller, developing device, process cartridge, and image forming apparatus |
| US20090170105A1 (en) * | 2007-11-08 | 2009-07-02 | Interleukin Genetics, Inc. | Diagnostics for Aging-Related Dermatologic Disorders |
| EP2304052A2 (en) * | 2008-05-02 | 2011-04-06 | Interleukin Genetics, Inc. | Detecting genetic predisposition to osteoarthritis associated conditions |
| ES2708826T3 (es) | 2008-05-02 | 2019-04-11 | Orig3N Inc | Detección de la predisposición genética a afecciones asociadas a la osteoartritis |
| SG191078A1 (en) | 2010-12-09 | 2013-07-31 | Interleukin Genetics Inc | Improved method and kit for determining severity and progression of periodontal disease |
| CA3011363A1 (en) | 2016-01-12 | 2017-07-20 | Interleukin Genetics, Inc. | Methods for predicting response to treatment |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| KR101894018B1 (ko) * | 2017-02-09 | 2018-08-31 | 주식회사 테라젠이텍스 | 치주 질환의 위험도를 예측하기 위한 조성물, 마이크로어레이, 및 키트, 및 이를 이용한 방법 |
| CA3142662A1 (en) | 2019-06-06 | 2020-12-10 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110920A (en) * | 1982-01-22 | 1992-05-05 | Cetus Corporation | HLA typing method and DNA probes used therein |
| US4582788A (en) * | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| DE3377363D1 (en) * | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4666828A (en) * | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4801531A (en) * | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US4992367A (en) * | 1986-05-12 | 1991-02-12 | Hoffmann-La Roche Inc. | Enhanced expression of human interleukin-2 in mammalian cells |
| US5268267A (en) * | 1987-08-21 | 1993-12-07 | The General Hospital Corporation | Method for diagnosing small cell carcinoma |
| US5158871A (en) * | 1988-02-12 | 1992-10-27 | University Of Connecticut | Method of using magnetic particles for isolating, collecting and assaying diagnostic ligates |
| US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5215895A (en) * | 1989-11-22 | 1993-06-01 | Genetics Institute, Inc. | Dna encoding a mammalian cytokine, interleukin-11 |
| US5328829A (en) * | 1990-07-05 | 1994-07-12 | Forsyth Dental Infirmary For Children | Method of determining sites of active periodontal disease |
-
1995
- 1995-08-03 US US08/510,696 patent/US5686246A/en not_active Expired - Lifetime
-
1996
- 1996-08-01 MY MYPI96003155A patent/MY132156A/en unknown
- 1996-08-02 SI SI9620098A patent/SI9620098A/sl unknown
- 1996-08-02 BR BR9604044A patent/BR9604044A/pt active Search and Examination
- 1996-08-02 NZ NZ315836A patent/NZ315836A/en unknown
- 1996-08-02 JP JP50848497A patent/JP4042811B2/ja not_active Expired - Fee Related
- 1996-08-02 AR ARP960103869A patent/AR003182A1/es unknown
- 1996-08-02 KR KR1019980700732A patent/KR19990036067A/ko not_active Withdrawn
- 1996-08-02 CA CA002228424A patent/CA2228424C/en not_active Expired - Lifetime
- 1996-08-02 EP EP96928022A patent/EP0853630A4/en not_active Ceased
- 1996-08-02 WO PCT/US1996/012455 patent/WO1997006180A1/en not_active Ceased
- 1996-08-02 CN CN96197316A patent/CN1198166A/zh active Pending
- 1996-08-02 AU AU67633/96A patent/AU719965B2/en not_active Ceased
- 1996-08-03 ZA ZA9606585A patent/ZA966585B/xx unknown
- 1996-08-03 TW TW085109393A patent/TW406130B/zh active
- 1996-08-05 PT PT96305770T patent/PT769560E/pt unknown
- 1996-08-05 ID IDP962236A patent/ID17246A/id unknown
- 1996-08-05 DE DE69616478T patent/DE69616478T2/de not_active Expired - Lifetime
- 1996-08-05 EP EP96305770A patent/EP0769560B1/en not_active Expired - Lifetime
- 1996-08-05 DK DK96305770T patent/DK0769560T3/da active
- 1996-08-05 AT AT96305770T patent/ATE207927T1/de not_active IP Right Cessation
- 1996-08-05 ES ES96305770T patent/ES2166866T3/es not_active Expired - Lifetime
-
1998
- 1998-01-19 IS IS4653A patent/IS4653A/is unknown
- 1998-02-02 NO NO980439A patent/NO980439L/no not_active Application Discontinuation
- 1998-02-02 MX MX9800941A patent/MX9800941A/es not_active IP Right Cessation
- 1998-10-26 IL IL12305398A patent/IL123053A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0853630A4 (en) | 1999-10-27 |
| US5686246A (en) | 1997-11-11 |
| JP4042811B2 (ja) | 2008-02-06 |
| DE69616478T2 (de) | 2002-08-08 |
| EP0853630A1 (en) | 1998-07-22 |
| SI9620098A (sl) | 1998-10-31 |
| WO1997006180A1 (en) | 1997-02-20 |
| DK0769560T3 (da) | 2002-02-18 |
| KR19990036067A (ko) | 1999-05-25 |
| BR9604044A (pt) | 1998-06-09 |
| JP2001517067A (ja) | 2001-10-02 |
| ES2166866T3 (es) | 2002-05-01 |
| ID17246A (id) | 1997-12-11 |
| CN1198166A (zh) | 1998-11-04 |
| NO980439L (no) | 1998-03-13 |
| AR003182A1 (es) | 1998-07-08 |
| IS4653A (is) | 1998-01-19 |
| MY132156A (en) | 2007-09-28 |
| NO980439D0 (no) | 1998-02-02 |
| ATE207927T1 (de) | 2001-11-15 |
| EP0769560A3 (en) | 1999-11-24 |
| EP0769560A2 (en) | 1997-04-23 |
| IL123053A (en) | 2000-01-31 |
| EP0769560B1 (en) | 2001-10-31 |
| MX9800941A (es) | 1998-10-31 |
| ZA966585B (en) | 1997-02-26 |
| IL123053A0 (en) | 1998-12-06 |
| PT769560E (pt) | 2002-04-29 |
| CA2228424A1 (en) | 1997-02-20 |
| AU719965B2 (en) | 2000-05-18 |
| AU6763396A (en) | 1997-03-05 |
| NZ315836A (en) | 1999-10-28 |
| CA2228424C (en) | 2005-12-27 |
| DE69616478D1 (de) | 2001-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW406130B (en) | Methods of in vitro predicting a patient's susceptibility to increase periodontal disease severity and the kits therefor | |
| Hočevar et al. | The possible influence of genetic aetiological factors on molar–incisor hypomineralisation | |
| Jouanguy et al. | A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection | |
| Agnese et al. | Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections | |
| Zhang et al. | Interferon‐gamma promoter hypomethylation and increased expression in chronic periodontitis | |
| Scarel‐Caminaga et al. | Investigation of an IL‐2 polymorphism in patients with different levels of chronic periodontitis | |
| Kim et al. | Mutational analysis of candidate genes in 24 amelogenesis imperfecta families | |
| Donati et al. | Association of the− 159 CD14 gene polymorphism and lack of association of the− 308 TNFA and Q551R IL‐4RA polymorphisms with severe chronic periodontitis in Swedish Caucasians | |
| Petkovic-Curcin et al. | Association of Cytokine Gene Polymorphism with Peri-implantitis Risk. | |
| Briseño-Ruiz et al. | Role of TRAV locus in low caries experience | |
| Citera et al. | Influence of HLA-DR alleles on rheumatoid arthritis: susceptibility and severity in Argentine patients. | |
| EP4534695A1 (en) | Genetic markers for diagnosis or prognosis prediction of degenerative temporomandibular joint osteoarthritis and use thereof | |
| Cao et al. | Association of matrix metalloproteinase‐1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population | |
| KR102887290B1 (ko) | 퇴행성 턱관절염의 진단 또는 예후 예측용 유전자 마커 및 이의 용도 | |
| Biedziak et al. | Identification of a new familial case of 3q29 deletion syndrome associated with cleft lip and palate via whole‐exome sequencing | |
| Cavallari et al. | The impact of MUC 5B gene on dental caries | |
| JP2019000082A (ja) | 侵襲性歯周炎の遺伝子検査および治療剤 | |
| JP2008534009A (ja) | 大腸癌診断用の多重ｓｎｐ、それを含むマイクロアレイ及びキット、並びにそれを利用した大腸癌の診断方法 | |
| Abbasoğlu et al. | Fine-mapping of Xq25. 1–27.2 shows association of early childhood caries with genetic variants depending on dietary habits, protecting children who drink milk before going to bed | |
| Hočevar et al. | Dataset on amelogenesis-related genes variants (ENAM and ENAM interacting genes) and on human leukocyte antigen alleles (DQ2 and DQ8) distribution in children with and without molar-incisor hypomineralisation (MIH) | |
| Sharma et al. | AMELX gene association to early childhood caries in south-Indian children: a case–control study | |
| US6524791B1 (en) | Spinocerebellar ataxia type 8 and methods of detection | |
| Sadputranto et al. | Association of Growth Hormone Receptor Gene Polymorphisms (rs6180, rs6182, rs6184) with Skeletal Class III Malocclusion and Prognathic Mandibles in the Deutero-Malay Race | |
| JP2006230241A (ja) | 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療 | |
| Poletta | Jessica Briseño-Ruiz, Takehiko Shimizu, Kathleen Deeley, Piper M. Dizak, Timothy D. Ruff, Italo M. Faraco |